If you work in oncology or infusion, you already know that biosimilars aren't coming; they're here. For most drugs, your team has figured out the clinical piece. You know the science, you understand interchangeability, and you've read the FDA approvals.

The part that keeps tripping people up isn't clinical. It's communication.

A recent Rhazdrugs implementation sparked a valuable discussion about how and why certain drugs end up on hazardous drug lists.

Remember 2004? Shrek 2 was breaking box office records, we were all singing "Yeah!" by Usher, and Facebook was just getting started. That same year, NIOSH published its first list of hazardous drugs in healthcare settings. It was a sample list of 34 drugs that would (slowly) grow into the list of 236 drugs NIOSH released in 2024.

Is it too late to say Happy New Year? Maybe Happy New NIOSH is more appropriate? 🥳

As you know, by the end of 2024, NIOSH delivered a present we’ve been waiting nearly nine years for. This present comes with a bag of screws and nails and that one tool that never works. In other words, we’re happy to have this guidance but it was not without some serious work to get the benefits.